Nicox’s Licensee Bausch + Lomb Launches VYZULTA® in Argentina
November 23, 2020
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive global licensee Bausch + Lomb has launched VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Argentina. Regulatory approval in Argentina was obtained in January 2020.
VYZULTA® is currently commercialized in the United States and Canada, and has also received approval in Hong Kong, Mexico, Taiwan and Ukraine for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bausch + Lomb will continue seeking approvals in territories where the clinical data package, part of the U.S. New Drug Application, can be used for approval by the regulatory authorities.
Under the terms of the exclusive license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestones payments.
Bausch + Lomb is a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC).